Testimony to FDA Endocrinologic and Metabolic Drugs Advisory Committee on Dapagliflozin for Treatment of Type 2 Diabetes Mellitus

View Slideshow as PDF.

Public Citizen urges the agency not to approve dapagliflozin, a member of a new chemical class of drugs to treat type 2 diabetes mellitus, because it is no more effective than a similar diabetes drug, canagliflozin, approved by the FDA in March 2013, but does appear to pose additional safety hazards not seen with canagliflozin, including risks of bladder cancer and liver toxicity.